For each session, participants reported to the laboratory at 0830 and remained until 1430. They were instructed not to eat breakfast before reporting to the laboratory and to refrain from using all psychoactive drugs (with the exception of tobacco, caffeinated products and alcohol) for the duration of their participation in the study. Participants were instructed not to drink alcohol 24 h prior to, or following a session. Upon arrival to the laboratory, a urine specimen was collected and a breath alcohol test was conducted (Alco-Sensor III, Intoximeters, Inc., St. Louis, MO). Urine specimens were analyzed for the presence of illicit drugs. Out of all the urine samples collected throughout the study, only two participants (both in the FHN group) had positive urine drug screens: one participant was positive for opioids on one session due to a previous dental procedure and another participant was positive for cannabinoids. There were no positive breath alcohol tests on any sessions. When possible, each menstrual cycle phase blood samples were drawn for hormone assays in the morning before the tasks began (between 9–10 am) with
